Intracranial Complications From Immune Checkpoint Therapy in a Patient With NSCLC and Multiple Sclerosis: Case Report

BACKGROUND: Immune checkpoint inhibitors (ICIs) have become an increasingly important tool in cancer treatment, revealing durable responses in several different types of tumors, including NSCLCs. Nevertheless, ICIs carry a risk of immune-mediated toxicities. There is a paucity of data for concurrent...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Benjamin Y., Isitan, Cigdem, Mahajan, Amit, Chiang, Veronica, Huttner, Anita, Mitzner, Jackson Robinson, Wesley, Sarah F., Goldberg, Sarah B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474265/
https://www.ncbi.nlm.nih.gov/pubmed/34590030
http://dx.doi.org/10.1016/j.jtocrr.2021.100183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474265/
https://www.ncbi.nlm.nih.gov/pubmed/34590030
http://dx.doi.org/10.1016/j.jtocrr.2021.100183

Ejemplares similares